Genentech reports Phase III CELESTIMO PFS improvement for Lunsumio
Genentech says its Phase III CELESTIMO study of Lunsumio (mosunetuzumab-axgb) plus lenalidomide vs Rituxan (rituximab) plus lenalidomide in relapsed/refractory follicular lymphoma showed significantly improved progression-free survival.
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), said it announced today that the Phase III CELESTIMO study of Lunsumio® (mosunetuzumab-axgb) in combination with lenalidomide, compared with Rituxan® (rituximab) plus lenalidomide, in people with relapsed or refractory follicular lymphoma…